- Q3 2025 Blowout & Stock Surge: Teva Pharmaceutical Industries (NYSE: TEVA) posted better-than-expected Q3 2025 results, with adjusted EPS of $0.78 (vs. $0.67 forecast) on revenue of $4.48 billion (vs. $4.34 billion est.) [1]. The earnings beat – Teva’s first this year – sent its stock soaring ~10–11% (to around $22–23, a new 52-week high) in early trading on Nov 5 [2] [3].
- Guidance Raised: On strong performance, Teva raised its 2025 outlook. It tightened full-year revenue guidance to $16.8–$17.0 billion (narrowing the range from a prior high end of $17.2B) and boosted adjusted EPS guidance to $2.55–$2.65 (up from $2.50–$2.65) [4]. Key growth drugs like Austedo prompted a $50–$100 million increase in that product’s sales forecast to $2.05–$2.15 billion [5] [6].
- Innovative Drugs Driving Growth: Teva’s “Pivot to Growth” strategy is paying off. Its innovative branded portfolio – led by Austedo (neurological disorders), Ajovy (migraine), and new schizophrenia injection UZEDY – grew revenues 33% YoY in Q3 (local currency) [7]. Austedo alone saw 38% YoY growth to $618 M [8], fueling Teva’s 11th consecutive quarter of YoY revenue growth [9]. Management touts this as evidence of a successful turnaround toward higher-margin innovative products [10].
- Improving Financial Health: Teva has been steadily paying down debt and cutting costs. Total debt was ~$16.79 billion as of Q3 2025, down from ~$17.78 billion at end-2024 [11]. Credit agencies have taken notice – Fitch upgraded Teva’s rating to ‘BB+’ (stable) in May 2025, citing “successful debt reduction efforts and improved financial flexibility,” expected growth from Austedo/Ajovy, and margin-boosting cost optimizations [12]. Teva’s non-GAAP operating margin hit 28.9% in Q3 (up ~0.86 percentage points YoY) [13], on track toward a 30% margin by 2027. Free cash flow was $515 M for the quarter (vs. $922 M a year prior) [14] – lower due to timing of cash expenses and fewer asset divestitures, but still solid for servicing debt and reinvestment.
- Stock Price & Valuation: After the post-earnings pop, TEVA trades around the mid-$22s – its highest level in over a year [15]. The stock has gained roughly 9–11% in the past 12 months and ~140% over the last 3 years, reflecting a dramatic recovery from past lows [16]. Despite this rally, valuation metrics appear modest: at ~$22/share and ~$2.6 EPS guidance, Teva’s forward P/E is ~8–9 (vs. pharma industry averages in the teens). Its price-to-sales is ~1.4×, notably below peer averages (~3–4×) [17], suggesting the stock remains undervalued relative to sector norms. A SimplyWall St DCF analysis even estimates an intrinsic value near $58, implying ~65% undervaluation at current prices [18].
- Analyst Sentiment – Bullish Upside: Wall Street is growing optimistic on Teva. The consensus rating is a “Buy/Strong Buy” with 7–8 analysts covering. Recent target price hikes include JPMorgan and UBS both lifting targets to $26 [19]. The average 12-month target hovers around $25–26, ~25% above current levels [20]. In total, 8 analysts tracked by MarketBeat assign 2 Strong Buys, 6 Buys, 1 Sell (no Holds), underscoring a positive outlook [21]. Many cite Teva’s turnaround progress and low valuation as rationale for further upside.
- Technical Analysis – Momentum at Highs: From a chart perspective, Teva’s stock has strong upward momentum. It recently broke out to new 52-week highs (~$22.80) [22], clearing potential resistance. Shares are now trading well above their 50-day (~$18.7) and 200-day (~$17.0) moving averages [23] – a bullish technical signal of an established uptrend. The stock’s relative strength has improved markedly following the earnings spike, though traders may watch for near-term consolidation after the rapid 10% jump. Beta is ~0.7, so Teva tends to be less volatile than the broader market [24]. Key support may lie around the high-teens if any pullback, while the next psychological resistance could be around the mid-$20s (coinciding with analysts’ targets and multi-year highs).
- Recent News Drivers:Late October–November 2025 brought multiple catalysts. In addition to earnings, an Israeli investment firm Phoenix Financial disclosed a major stake increase in Teva, making it the fund’s #2 holding (6.8% of AUM) with 41.3 million shares (~$834M) [25] [26]. This vote of confidence in Teva’s “flagship” status in Israel signals institutional bullishness on CEO Richard Francis’s turnaround plan focusing on debt reduction, cost savings, and biosimilars/complex generics [27] [28]. On the legal front, Teva reached a $35 million settlement on Oct. 27 to resolve a U.S. antitrust lawsuit over its QVAR asthma inhaler, while agreeing to withdraw certain patents to allow generic competition [29] [30]. This minor payout helps clear lingering legal overhang without material impact on finances. Separately, the U.S. Inflation Reduction Act’s drug price negotiations concluded for 2025; Teva noted it “reiterates strong confidence” in Austedo’s long-term targets after IRA talks, indicating no adverse pricing surprise for that key drug [31].
- Regulatory & Litigation Outlook: Teva has largely put major litigation risks in the rearview mirror. It finalized a $4.25–$4.35 billion nationwide opioid settlement in 2022 to resolve thousands of lawsuits (to be paid over 13 years, partly via medication contributions) [32] [33]. And in 2023, Teva paid $225 M to the DOJ to settle price-fixing allegations [34] [35]. With these legacy issues addressed, Teva’s risk profile is improving. Regulatory-wise, the company continues to work through industry challenges like U.S. drug pricing pressures. It is also in the process of divesting its API (active ingredients) unit to streamline operations – exclusive talks with one buyer fell through, but Teva just restarted the sale process while maintaining the intent to sell [36]. Any proceeds could further trim debt. On the product side, Teva recently launched generic Saxenda (liraglutide) – the first generic GLP-1 weight-loss injection approved by the FDA [37] – tapping into the booming obesity drug market. It also launched several biosimilars (for Humira, Stelara, Soliris) which are contributing to growth [38]. Upcoming pipeline milestones include an expected FDA filing in Q4 2025 for Teva’s long-acting schizophrenia injection (olanzapine LAI) [39], and progress in Phase 3 trials for innovative therapies in multiple system atrophy and ulcerative colitis [40]. These developments underscore a shift toward higher-value products and could add long-term revenue streams if successful.
Financial Health and Earnings Trends
Teva’s financial turnaround appears to be gaining steam, driven by both top-line growth and disciplined cost management. Quarterly revenue has now grown year-over-year for 11 straight quarters [41], marking a sustained rebound after a difficult past decade. In Q3 2025, revenue rose ~3% YoY (1% in constant currency) to $4.48 B [42], while adjusted earnings jumped to $0.78 per share (from $0.69 a year ago) [43]. Notably, this beat Wall Street estimates by ~$0.10 and marked Teva’s strongest earnings surprise of 2025 [44]. The growth engines are Teva’s newer branded drugs: movement-disorder treatment Austedo, migraine injection Ajovy, and schizophrenia depot UZEDY. Together these “innovative medicines” climbed 33% YoY (local currency) and contributed $830 M this quarter [45], helping offset flat-to-declining sales in older generic categories. “Our key innovative brands…delivered a 33% increase…underscoring their impact on both patient outcomes and our financial performance,” CEO Richard Francis noted [46] [47]. Importantly, Austedo’s momentum (global sales +38% YoY) led management to raise Austedo’s 2025 revenue outlook to $2.05–$2.15 B [48]. This bodes well for continued earnings expansion, since these specialty products carry higher margins than commodity generics.
Meanwhile, Teva’s core generics business – still the world’s largest generic drug franchise – is stable to modestly growing in key markets. In the U.S., generic and biosimilar revenues grew ~7% YoY in Q3 [49], aided by new launches (e.g. the first generic Saxenda for weight loss [50]) and biosimilars. However, some international generics segments saw declines due to divestitures (Teva exited its Japan venture earlier in 2025) [51]. Overall, the portfolio mix shift toward higher-value products is evident: Teva’s U.S. sales jumped 12% YoY [52], far outpacing overall growth, thanks to its innovative drugs and complex generics strategy. This is a positive sign that Teva’s “Pivot to Growth” plan – launched in 2023 under the new CEO – is yielding tangible results.
On profitability, margins are improving despite inflation and pricing pressures. Teva reported a 28.9% non-GAAP operating margin in Q3 [53], inching closer to its goal of 30% by 2027. Executives attribute this to ongoing cost savings programs (targeting ~$700 M in net savings through 2027) and better product mix. The firm is aligning spending to high-impact areas and modernizing operations, which Fitch Ratings also noted as supporting margin expansion [54] [55]. Cash flow generation remains robust: Teva delivered $1.1 B in free cash flow in the first nine months of 2025 (though Q3’s $515 M was down YoY) [56]. This cash is being plowed into debt repayment and selective growth investments.
Crucially, Teva’s balance sheet health is steadily rebounding from the leverage peak of past years. The company’s net debt (debt minus cash) is now in the mid-$15 B range [57], down substantially from ~$34 B in 2016–2017 after the ill-fated Allergan generics acquisition. As of Sept 30, 2025, total debt was $16.79 B (vs. $17.78 B at 2024 year-end) [58], reflecting nearly $1 B of paydown in 9 months. Teva repaid $1.8 B in senior notes in early 2025 [59] and even conducted debt tender offers to retire obligations ahead of schedule [60], signaling confidence in its cash position. Debt-to-equity stands around 2.45× [61] – still high, but much improved as equity value has recovered. Management is targeting a net debt/EBITDA ratio ~2.0× by 2027, a goal that appears attainable if earnings grow and debt reduction continues [62]. The credit rating upgrades by Fitch (to BB+) and earlier by Moody’s underscore this positive trajectory [63]. In short, Teva’s financial footing – while not without remaining leverage – is substantially more solid than a few years ago, giving it greater flexibility to invest in R&D and pipeline opportunities.
It’s worth noting that on a GAAP basis Teva’s bottom line has been dampened by one-time charges (legal settlements, impairments). Trailing 12-month net income is slightly negative (~$157 M loss) [64], yielding a GAAP P/E that’s not meaningful (MarketBeat lists a P/E of –125 due to these charges) [65]. However, on an adjusted basis Teva is strongly profitable and growing. For full-year 2025, the company expects adjusted EPS ~$2.55–$2.65 [66], which would be roughly 10% growth over 2024’s normalized earnings. The improving earnings trend, combined with debt reduction, speaks to a company in recovery mode financially – turning the corner from a period of crisis to one of cautious growth.
Current Stock Price and Valuation Metrics
Teva’s stock has staged an impressive comeback, yet many analysts argue valuation remains attractive. After the early November rally, TEVA trades around $22–23 per share, the highest level the stock has seen in about 5–6 years. It’s up roughly 10% year-to-date in 2025 (though it lagged some pharma peers earlier in the year) and has more than doubled from its 2022 lows. In fact, from late 2022 to late 2025, Teva shares have climbed ~140% [67] – a testament to the market’s growing confidence in the turnaround. Despite these gains, Teva’s valuation multiples still trail the sector. At ~$22/share and ~$2.60 in forward earnings, Teva’s forward P/E sits around 8.5. This is markedly below the S&P 500’s ~18 and even below other generic-drug makers. Part of the discount is due to Teva’s debt load and remaining legal/regulatory overhang, but it suggests upside if the company continues executing.
Other metrics reinforce the value case. Teva’s price-to-sales (P/S) ratio is ~1.4× (using ~$17B revenue), which is dramatically lower than the pharmaceutical industry average (~4.2×) and even peers in generics (~3.1×) [68]. In other words, investors are valuing Teva at only ~1.4 times its annual sales, whereas many pharma companies trade at 3–4+ times sales. This could imply the market is still pricing in a lot of risk or low growth for Teva. However, if Teva delivers mid-single-digit revenue growth (as current guidance and pipelines suggest) and expands margins, that low P/S and a forward PEG ~1.1 [69] signal a potentially undervalued stock. A DCF analysis by Simply Wall St lends credence to this view – their model estimates Teva’s intrinsic value around $58/share, which is ~165% above the current price (implying the stock is ~65% undervalued) [70]. While that may be an overly rosy scenario, it highlights how much skepticism remains embedded in Teva’s price.
In terms of enterprise value, Teva’s EV/EBITDA is in the high-single digits (rough estimate ~7–8× using 2025 EBITDA ~$4.9B). That’s relatively low for a major pharma, reflecting both the debt and the “no-moat” nature of generics. Notably, Teva pays no dividend (it halted dividends in 2017 to conserve cash), which some income-focused investors avoid – but also means more cash is directed to debt paydown and growth efforts. If leverage continues to fall, Teva could potentially revisit capital returns in a few years, although for now management’s priority is balance sheet strength.
It’s important to contextualize Teva’s valuation against its competitive landscape. Pure-play generic peers like Viatris (VTRS) and Sandoz trade at low multiples as well, since generic drug pricing can be volatile and growth is modest. Teva’s emerging specialty drug portfolio, however, gives it a growth kicker and slightly higher margin profile than a pure generic firm. Should Teva’s branded drugs (Austedo, Ajovy, UZEDY, etc.) continue to expand, the company could start to warrant multiples closer to specialty pharma companies. At present, the market remains somewhat cautious – essentially taking a “wait and see” approach on whether Teva can hit its 2027 targets (30% margin, $2.5B+ Austedo sales, 2× leverage). If those targets start coming into clearer focus, there is room for multiple expansion. For instance, even a modest re-rating to a P/E of 12 (still below market average) on ~$2.60 EPS would imply a stock price around $31 (roughly 40% above current). In sum, Teva’s stock appears reasonably cheap relative to its earnings and peers, though unlocking that value hinges on sustaining the turnaround trajectory.
Recent News and Catalysts (Late Oct – Early Nov 2025)
The days surrounding November 5, 2025 have been eventful for Teva, bringing a flurry of news that propelled the stock and shaped investor sentiment:
- Q3 2025 Earnings Beat & Guidance Hike (Nov 5): The headline event was Teva’s third-quarter earnings announcement on Nov 5, which blew past expectations. As noted, Teva beat on both profit and revenue and raised its full-year forecasts [71]. This was the first quarterly beat in some time and a clear signal that Teva’s cost cuts and new product sales are yielding results. The stock’s double-digit percentage jump on the news (up ~9% in Tel Aviv, +11% pre-market in New York) [72] [73] indicates how surprised and encouraged investors were by the strength of the report. In the earnings call, CEO Richard Francis highlighted the “accelerating momentum” of Teva’s transformation and reiterated confidence in hitting long-term goals [74]. The positive earnings news not only lifted Teva’s shares but also grabbed media headlines, potentially attracting new investors who had been on the sidelines.
- Institutional Investment Vote of Confidence (disclosed Nov 3): Just days before earnings, it came to light via SEC filings that Phoenix Financial Ltd., a large Israel-based institutional investor, boosted its stake in Teva significantly during Q3. Phoenix bought ~3.5 million additional shares, bringing its total to 41.3 million shares valued at ~$834 M – making Teva its second-largest holding (6.8% of assets) [75] [76]. This is a noteworthy development because Phoenix is effectively doubling down on Teva as a core investment. The timing (Q3) suggests Phoenix anticipated that Teva’s turnaround was gaining traction. Phoenix’s rationale, as reported by The Motley Fool, was that Teva is “stabilizing under CEO Richard Francis’s turnaround plan, which emphasizes debt reduction, cost savings, and a pivot toward biosimilars and complex generics” [77]. Such a high-conviction bet by a major investor sent a bullish signal to the market, reinforcing the idea that smart money sees value in Teva’s recovery story. The news of Phoenix’s stake (and similarly, reports that other Israeli institutions like Menora Mivtachim took 5%+ stakes [78]) may have contributed to Teva’s stock strength in late October as it suggested rising institutional confidence.
- Legal Resolution – Inhaler Antitrust Settlement (Oct 27): On October 27, Teva agreed to pay $35 million to settle a class-action lawsuit alleging it delayed generic competition for its QVAR asthma inhaler [79]. As part of the deal (awaiting court approval), Teva will also withdraw six disputed patents from the FDA’s listings to allow generic QVAR entrants [80]. This lawsuit was a relatively minor overhang, but its resolution is positive in that it closes the book on another piece of litigation. Importantly, Teva admitted no wrongdoing in the settlement [81]. For investors, the $35M payout is immaterial (just ~$0.03 per share after tax), but it eliminates the risk of a protracted legal battle and any potential injunctions. The context here is that Teva – like many pharma companies – faces periodic antitrust suits over “pay-for-delay” or patent strategies. By settling, Teva avoids uncertainty and legal costs. This news likely had a neutral-to-positive effect on the stock, reinforcing the narrative that Teva’s legal troubles are gradually clearing up.
- IRA Price Negotiation Conclusion (late Oct): Another recent development was the conclusion of the first round of Medicare price negotiations under the U.S. Inflation Reduction Act. While Teva has a smaller U.S. branded portfolio than big pharma peers, its leading drug Austedo (for Huntington’s and tardive dyskinesia) could have been a candidate for future price negotiation given its growing sales. Teva noted that after the IRA negotiations, it is “reiterating strong confidence” in its Austedo 2027 target [82]. This implies that any pricing concessions Teva might have to make on Austedo for Medicare in coming years are manageable and won’t derail its growth trajectory. In other words, no nasty surprises emerged from IRA talks for Teva, which is a relief for investors worried about U.S. pricing pressure. It’s also worth noting Teva got a label expansion for Ajovy in October (FDA approved Ajovy for use in preventing episodic migraine in adolescents) [83] – a small win that could modestly expand Ajovy’s market.
All told, the past couple of weeks delivered a series of encouraging news for Teva – strong earnings, insider-like buying from a major fund, legal clean-up, and constructive regulatory outcomes. This confluence of factors helped create a more bullish sentiment around the stock as of early November 2025.
Expert Commentary and Analyst Views
Analysts and experts are increasingly optimistic that Teva’s turnaround is real – and that the stock has more room to run. The recent earnings beat prompted a wave of positive commentary. For example, J.P. Morgan analysts reaffirmed their overweight stance, raising their price target from $23 to $26 in October [84], citing Teva’s improving growth outlook. UBS similarly boosted its target to $26 (from $23) while maintaining a “Buy” rating [85]. These target hikes just ahead of earnings suggest that Wall Street was already seeing underappreciated strength in Teva’s business.
The consensus 12-month price target now stands around $25.5 [86], about 25% above the current price – indicating analysts collectively see significant upside. Ratings-wise, no major firm recommends selling Teva at this point. According to MarketBeat data (as of mid-October), Teva had 2 Strong Buy, 6 Buy, 0 Hold, 0 Sell, 1 Strong Sell ratings [87]. The lone dissent came from an independent research outfit (Weiss Ratings) that issued a “sell” in early October [88], but mainstream equity analysts universally lean bullish. Market consensus is a “Buy/Strong Buy” for TEVA [89]. This is a stark change from just a couple years ago when Teva was often viewed as high-risk and was sparsely covered by bulls.
Quotes from management also reflect a confident tone that experts echo. CEO Richard Francis stated that Q3’s results “reflect the accelerating momentum of our transformation and the strength of our innovation-led Pivot to Growth strategy” [90]. He emphasized that Teva is “firmly on track” to hit its 30% margin and cost savings targets [91], and highlighted how the “differentiated innovative portfolio is now a defining strength for Teva” [92]. This narrative – that Teva is no longer just a struggling generics giant, but an emerging innovative player – is resonating with analysts. Fitch Ratings, in upgrading Teva’s credit, effectively provided a form of expert commentary too: Fitch cited Teva’s “successful debt reduction efforts and improved financial flexibility” and noted the firm’s focus on optimizing operations and a “promising biosimilar pipeline” as reasons for confidence [93]. In other words, even credit analysts see the company executing well on its plan.
On financial blogs and stock forums, Teva is often discussed as a “value play” with catalysts. Zacks Equity Research recently highlighted Teva as a top value pick, noting the stock’s low multiples and the fact that analysts’ earnings estimates for Teva have been rising (a bullish sign in their quantitative model) [94]. Simply Wall St’s analysis (referenced earlier) outright asked if Teva is a value opportunity after the share price jump, concluding the stock “is currently substantially undervalued” based on multiple approaches [95] [96]. Some commentators point to Teva’s past troubles (opioid litigation, high debt) and note those are largely resolved or priced in, whereas the future – with new products like Austedo, Ajovy, UZEDY, and a leaner cost base – is not fully appreciated by the market yet.
That said, experts do caution that risks remain. One remaining bear (the Weiss analyst) gave Teva a low grade, presumably due to the still-heavy debt and the fact that Teva’s core generics business faces ongoing price erosion. Morningstar, which maintains a more tempered outlook, might classify Teva as “no-moat” (lacking sustainable competitive advantage) and previously had concerns about long-term growth. However, even Morningstar’s analyst acknowledged recent earnings were “better-than-expected” and that Teva’s restructuring is yielding benefits (noting improved margins and stable Copaxone sales in a prior commentary). The overall sentiment in late 2025 is that Teva’s worst days are behind it, and multiple analysts have used the phrase “turnaround” or “comeback” to describe its current state [97]. The question they debate is not if Teva will continue improving, but how quickly and how far the improvement can go – which will determine just how undervalued the stock truly is.
In summary, the expert and analyst community is largely in agreement that Teva is on the right track. With upward earnings revisions, bullish price targets, and high-profile investors buying in, the stock has a favorable wind at its back. As long as Teva can keep executing (hitting financial targets, launching pipeline drugs, reducing debt), analysts suggest there is significant upside potential from here.
Technical and Fundamental Stock Analysis
Fundamental Analysis: Fundamentally, Teva’s investment case centers on a classic turnaround value story with emerging growth elements. On fundamentals, the key positives include improving earnings (with double-digit EPS growth and expanding margins), a clear debt reduction trajectory, and new products driving revenue mix shift. Teva’s earnings quality is also getting better – less reliant on one-offs like cost-cutting or legal settlements, and more driven by organic sales growth. The raised guidance for 2025 shows management’s confidence and provides tangible benchmarks: if Teva hits ~$2.60 EPS this year and can grow that further in 2026+, the stock is exceedingly cheap at under 9× earnings. Free cash flow generation (expected $1.6–$1.9 B in 2025 [98]) easily covers obligations and could accelerate de-leveraging or strategic investments (Teva has been investing in biosimilars and branded R&D more heavily since 2023). Another fundamental point is Teva’s tax advantage – being based in Israel with operations globally, its tax rate is relatively low, which boosts net margins compared to U.S.-based peers.
However, from a fundamental risk standpoint, investors should keep an eye on a few factors. Generic drug price erosion is a perpetual headwind; even as Teva focuses on complex generics, the base business can decline in low-to-mid single digits if not replenished with new launches. The Q3 results showed some weakness in Europe/international generics [99], reminding that competition is fierce. Branded drug competition is another concern: Austedo, while growing fast, competes with Neurocrine’s Ingrezza (and potentially new entrants for tardive dyskinesia in the future); Ajovy is one of three CGRP migraine injectables (with Amgen’s Aimovig and Lilly’s Emgality also on the market, plus oral migraine drugs like Nurtec competing). So, sustaining high growth in these products will require commercial execution and possibly new indications (Teva is working on an Ajovy pen device and that new pediatric indication [100], for example). Pipeline success is not guaranteed – while Teva has promising Phase 3 programs (like the olanzapine LAI for schizophrenia and the TEV-56286 for MSA), these are in competitive or uncertain areas. Fundamentally, though, Teva doesn’t need huge pipeline wins to justify its valuation; even moderate progress with its current portfolio could drive solid earnings.
One fundamental metric to watch is Teva’s interest expense in a rising rate environment. With ~$16B of debt, higher interest rates can eat into profits as older debt rolls over. Teva has managed this by paying down and refinancing when possible, and Fitch noted its financial discipline in keeping leverage in check [101]. As long as EBITDA grows and debt falls, interest coverage should improve, but it’s a lever to monitor since it affects net income directly (a reason GAAP profits have been anemic).
In sum, the fundamental analysis paints Teva as a company with improving financial metrics and undervalued stock ratios, balanced against an industry that is low-growth and competitive. If the “Pivot to Growth” strategy continues delivering (mid-single-digit revenue growth, margin expansion, debt paydown), then fundamentals indicate significant upside potential for the stock. Conversely, any slip in execution or unexpected setback (e.g. a large legal loss, a major product failing) could remind investors of Teva’s past and pressure the valuation again. So far, fundamentals are trending favorably.
Technical Analysis: On the technical side, Teva’s chart has turned decidedly bullish in 2024–2025. After basing in the low teens in 2022, the stock broke out above a multi-year resistance around $12–$15 in 2023 and has since been in an uptrend, with a remarkable 111% surge in 2024 alone [102]. Moving into 2025, the stock saw some consolidation in the mid-to-high teens, but the recent rally pushed it to new highs for the year ($22.80) [103]. This also marks a break above the prior 52-week high, confirming a fresh upswing. The 50-day moving average (~$18.69) is sloping upward and the stock is trading comfortably above it, indicating short-term momentum is positive [104]. More impressively, Teva is well above its 200-day MA (~$17.02) [105], a sign of long-term trend strength. The widening gap between the 50-day and 200-day (a “golden cross” occurred earlier in the year) often suggests strong technical underpinning for further gains.
Volume spiked on the earnings news, which is a bullish confirmation – big upward price movement on high volume signals institutional buying rather than just retail. The stock’s relative strength index (RSI) likely moved into overbought territory after the 10% one-day jump, so some near-term cooling or pullback could happen as traders take profits. A healthy consolidation above ~$20 would be constructive, establishing that level as new support. If the stock were to retrace, the previous resistance around $18 (near the 50-day MA) might serve as a support floor. Conversely, on further rallies, technical resistance might emerge around the mid-$20s; aside from being round-number territory, $25 was roughly a peak analyst target and could be a psychological hurdle, plus it’s near a long-term declining trendline if one connects highs from many years ago.
Notably, Teva’s 52-week range is $12.47 – $22.80 [106], so the stock is at the top of its yearly range. The fact it’s making higher highs and higher lows is the definition of an uptrend. Momentum indicators are positive: MACD likely crossed bullishly months ago, and the on-balance volume has improved as institutional interest (like Phoenix) picked up. Beta at ~0.71 means Teva is less volatile than the market overall [107] – interestingly, in 2022 when Teva was under heavy litigation clouds, it had a higher beta, but as stability returned, the stock’s movements became more orderly. This lower beta can make Teva a somewhat defensive play relative to high-flying biotech stocks, even while it offers high return potential.
From a trading perspective, some might view the recent gap-up as a breakaway gap on earnings – often a sign of the start of a new leg higher if the gap holds. Others might be cautious that after such a run (stock +142% in 3 years [108]), a period of sideways movement could occur to digest gains. The lack of any heavy overhead resistance (since the stock hasn’t traded in the mid-$20s since ~2017) means if positive catalysts continue, there’s room to run before hitting any historical supply zones. Long-term, if Teva’s turnaround fully materializes, one could even envision a return to pre-2017 levels (back then the stock was $30+ before its collapse). That’s speculative at this stage, but technically, the stock has broken out of its downtrend and is building a base for potential further appreciation.
In summary, technical analysis confirms the bullish case – Teva stock is in an uptrend, has strong momentum, and recently signaled another breakout with the earnings news. Traders will watch that key support levels (like $18–$20) hold on any dips. As long as the broader market is stable and Teva’s fundamentals keep improving, the technical picture suggests more upside is possible, with $25 and then $30 as the next potential resistance levels, while support lies around $18 and then $15 (the latter being the breakout zone from late 2023). Technical and fundamental analyses are aligned here: both point toward a stock that is climbing out of a deep valley, with improving strength in both the company’s finances and the stock’s price action.
Forecast and Investment Outlook
Looking ahead, Teva’s outlook appears positive but not without challenges. The company’s own forecast for 2025, now upgraded, provides a baseline: ~$16.9 B revenue and $2.55–$2.65 EPS [109]. This would represent modest top-line growth (~2-3% YoY) and solid bottom-line growth (~7-9% YoY) from 2024 levels. Analysts largely concur with this trajectory – the consensus is for flat-to-low-single-digit revenue growth in 2026 (to ~$17.3 B) [110] and a high-single-digit EPS increase (to ~$2.82 in 2026) [111]. So, in the short term (6–12 months), Teva is expected to grind out continued improvements, driven by its current product lineup and cost efficiencies. The raised guidance and recent performance reduce the risk of near-term disappointment, though execution (e.g. hitting the higher Austedo sales target) will be key. Any quarter that slips could jolt the stock given the high expectations now building.
In the short-term trading horizon, investors will also be eyeing a few catalysts: the Q4 2025 earnings report (likely Feb 2026) where Teva’s full-year results and 2026 guidance will be revealed – this could be a major stock mover. Also, any announcement of a successful sale of the API division in the coming months could be a catalyst, as it might bring a cash influx (potentially $2B or more, based on speculation) and improve margins by removing a lower-margin business. Regulatory approvals or launches, such as the olanzapine LAI schizophrenia drug (if the NDA is filed in Q4 2025, approval could come in late 2026), are more medium-term but could start influencing sentiment earlier if data is positive.
For the long term (1–3 years and beyond), Teva’s investment outlook will hinge on how well it can deliver on the promises of its Pivot to Growth strategy. By 2027, Teva aims for >$2.5 B in Austedo sales (annual) [112], operating margin ≥30%, and net debt/EBITDA ~2x or less. Hitting these targets would likely mean EPS well above $3 and a far stronger balance sheet – which, if achieved, would warrant a much higher stock price than today. The consensus 12-month price target of ~$25.5 [113] suggests that analysts see a path for at least a 25% gain in the next year. Some are even more bullish: e.g., Goldman Sachs initiated coverage in mid-2025 with a “Strong Buy” and a $24 target [114] [115] when the stock was much lower, implying they see significant long-term value.
Potential upside drivers in the long-term outlook include:
- Successful pipeline commercialization: If one of Teva’s pipeline assets (for example, the MSA treatment or the TL1A inhibitor for ulcerative colitis in partnership with Sanofi [116]) hits the market, it could open new revenue streams. Teva is also developing biosimilars to blockbuster biologics – continued success there (such as its biosimilar Humira, Stelara, and others gaining share) will add to growth.
- Biosimilar/Biologic Expansion: Teva has signaled a pivot toward biosimilars and complex generics (like high-tech injectables, inhalers, etc.) [117]. This positions Teva in growing niches of the generics market that are more insulated from price wars. If Teva becomes a leader in biosimilars (which is plausible given its partnerships and manufacturing scale), it could capture a nice chunk of the billions in biologics going off-patent over the next decade.
- Macro factors: Any tailwind in healthcare spending, such as an aging population requiring more medications, generally benefits large generic manufacturers like Teva through volume increases. Additionally, if foreign exchange rates stabilize (a strong dollar has previously hurt Teva’s reported sales since a lot comes from Europe/emerging markets), that could help reported results.
On the downside/risk side for the outlook:
- Competition and Pricing: The generic industry is notorious for price deflation. Teva’s size gives it an edge in economies of scale, but nimble competitors (from Indian pharma to new U.S. generic entrants) continuously pressure pricing. The competitive landscape includes not just traditional peers like Viatris and Sandoz, but also smaller generic firms and new biosimilar rivals. Teva must continue launching new products to replace declining older ones. Its Copaxone (once a flagship MS drug) is now a minor contributor due to generics; by late 2025 Copaxone sales have dwindled, and while that headwind is mostly done, it exemplifies how brand cliffs can hurt.
- Regulatory changes: If governments in the U.S. or EU aggressively reform drug pricing, it could compress margins. For instance, Medicare negotiation under IRA will expand to more drugs over time – Teva’s Austedo could face a negotiated price by late this decade if it stays among top spend drugs. Also, regulatory approval hurdles for biosimilars or complex generics could delay some of Teva’s pipeline launches.
- Execution risks: Turnarounds don’t always go smoothly. Teva needs to continue integrating its operations (after years of restructuring) and avoid operational slip-ups. The fact that free cash flow was down this quarter shows there can be variability; management will need to show that was temporary. Also, as Teva sheds non-core assets (like the API unit, and previously its oncology unit in Japan), ensuring that doesn’t disrupt supply chains or revenue more than expected is important.
Investor Outlook: For investors considering Teva now, the stock presents a mix of value and improving growth – an appealing combination for many value-oriented or GARP (growth at a reasonable price) investors. The short-term outlook (next few months) likely hinges on continued delivery of earnings in line or above expectations. Any confirmation of the 2025 guidance with Q4 results, or further positive surprises (e.g., faster debt paydown, higher Austedo sales, etc.), could serve as catalysts to push the stock toward that ~$25–26 consensus target. In contrast, any stumble (like an unexpected legal charge or a disappointing quarter) might cause a pullback to the high-teens.
In the medium term (1–2 years), the stock’s trajectory will probably follow the trajectory of the debt and earnings. If by the end of 2026 Teva has, say, <$14B debt and ~$3 EPS, the market may reward it with a higher multiple and price perhaps in the $30s (this is speculative, but within reason given peer valuations). Additionally, as the company’s risk profile improves (post-opioid litigation, lower leverage), a broader set of investors (including perhaps those who shunned it due to ethical or risk concerns) might be willing to buy in, supporting the price.
One should also consider that M&A dynamics in pharma could play a role in the long term. A leaner, more innovative Teva could become an acquisition target or could consider mergers (though antitrust issues would loom large given Teva’s generics dominance). While nothing specific is on the horizon, the sector often sees consolidation, and Teva’s low valuation might attract interest if it demonstrates sustained growth.
In conclusion, the investment outlook for Teva as of November 2025 is cautiously optimistic. Short-term, the stock has strong momentum from recent wins, and analysts see continued upside over the next year. Long-term, Teva is positioning itself as a more balanced pharma company – leveraging its generics muscle while cultivating select high-value branded and biosimilar products – which could deliver steady growth and significant debt reduction by late this decade. If management executes, investors could see substantial returns from today’s levels, as the market closes the valuation gap. As always, risks (competition, regulation, execution) need to be monitored, but Teva’s narrative has shifted from one of a debt-laden laggard to that of a potential comeback story in healthcare. With a below-market valuation, improving financial metrics, and a clearer growth path, Teva offers an intriguing mix of value and growth for investors heading into 2026.
Competitive Landscape and Sector Comparison
Teva operates at the crossroads of the generic pharmaceuticals industry and the specialty drug sector, so it’s instructive to compare it on both fronts. In the generic drug arena, Teva is the largest global player, producing a vast range of off-patent medicines. Its main competitors include Viatris (the Pfizer-Mylan spin-off), Sandoz (recently spun off from Novartis), India-based firms like Sun Pharma or Dr. Reddy’s, and other regional generic makers. Historically, this sector has been characterized by razor-thin margins, fierce price competition (especially in the U.S.), and periodic supply disruptions. Over the last few years, many generic companies faced pricing pressure that shrank revenues and profits – Teva was no exception, which is why it embarked on drastic cost cuts around 2018. By comparison, Teva’s scale and portfolio breadth give it an edge: it can produce drugs at lower unit costs and has a presence in higher-barrier segments (complex generics like inhalers, injectables, transdermals, etc.). For instance, Teva’s ability to launch the first generic GLP-1 weight-loss drug (liraglutide) [118] demonstrates how it can leverage its R&D and regulatory prowess to beat competitors to market in lucrative niches. In the generics world, being first-to-file or early to market on big drugs (like weight-loss treatments or biosimilars of top biologics) is crucial – Teva’s pipeline of ~75 pending generic approvals and dozens of biosimilars positions it well vs. peers, provided it executes on development.
Financially, compared to Viatris or Sandoz, Teva now has a higher growth rate (thanks to its specialty segment) but also carries more debt. Viatris, for example, has been relatively stagnant on revenue and trades at low multiples, but it pays a dividend. Teva chose to reinvest rather than pay dividends, aiming for growth which could differentiate it if successful. The sector average P/E for generic-focused firms is around 5–8, reflecting low growth expectations. Teva’s forward P/E (~8) is at the higher end of that range, justified by its growth in branded products. So within the generic peer group, Teva is emerging as a leader with a growth kicker, whereas others like Viatris are still mostly value plays with minimal growth (Viatris has been selling off pieces of its business and focusing on biosimilars too, but its revenue has been declining).
In the specialty drug sector, Teva’s competition is more fragmented and specific to each product. Austedo’s competitors include Neurocrine Biosciences (Ingrezza) for tardive dyskinesia; Ajovy’s competitors are Amgen’s Aimovig and Lilly’s Emgality in migraines; UZEDY’s competitor is primarily Johnson & Johnson’s Invega Hafyera and other schizophrenia long-acting injectables. Teva’s specialty portfolio is relatively small in number, but those products are carving out a space and growing fast. The neuroscience niche (movement disorders, migraine, psychiatry) is an area Teva is focusing on – here it competes with mid-sized biotechs and big pharma. For example, in migraine, the CGRP class competition means Teva must differentiate Ajovy (they’ve done so with quarterly dosing and now a pediatric use approval). Austedo, meanwhile, has held its own against Ingrezza by expanding into Huntington’s chorea (where it’s the only approved drug in the U.S.). In these specialty areas, Teva’s challenge is to keep innovating and improving its products (e.g., new formulations, new indications) because unlike with generics, the battle is on efficacy, safety, and marketing. The upside is that these markets are large and growing, and Teva’s share in each is still modest – so there’s room to gain if they execute well.
From a sector standpoint, Teva straddles “Big Pharma” and “Generics”. Big Pharma companies (Pfizer, J&J, Merck, etc.) trade at higher multiples (P/E often 12–15+) but have large R&D engines and patented drug portfolios. Teva doesn’t have a portfolio of novel blockbusters like they do (aside from its legacy drug Copaxone for MS, which was a blockbuster but is now generic). However, Teva’s current market cap ~$23B [119] is a fraction of those giants, and even smaller than specialty firms like Moderna or Regeneron. It’s perhaps more aptly compared to specialty/generic hybrids like Hikma Pharmaceuticals or Organon. In Israel, Teva has been the flagship pharma, but globally it’s a mid-cap pharma now. If Teva can continue growing its specialty segment, it could start to command a bit more of a pharma-like multiple rather than a pure generic multiple.
One important aspect of the competitive landscape is biosimilars. Teva is partnering with giants (like it partnered with Celltrion for some biosimilars, with Alvotech for others, and with Bioeq for a Lucentis biosimilar, etc.). The biosimilar market is heating up, with multiple players chasing each biologic. Teva’s competition here includes Biocon (with Viatris), Sandoz, Amgen, Pfizer (all have biosim arms), and newer entrants like Coherus in the U.S. The fact that Teva’s biosimilars (e.g., to Humira and Stelara) launched around the same time as others means it needs to leverage its strong commercial network to capture share. The early signs are positive – Teva noted its recently launched biosimilars (to Humira, Stelara, Soliris) “continue to grow” [120], contributing to U.S. growth. Winning in biosimilars is crucial because it’s a big piece of the future generics pie, and Teva aims to be a leader there.
In terms of sector performance, pharma and biotech stocks in 2025 have been mixed – big pharma had been relatively stable or down due to pricing worries, whereas biotech had some rallies. Teva’s stock, up ~9% in a year [121], actually underperformed the S&P 500 (~20% gain over the same period) [122], but outperformed many pharma peers that struggled in 2025. For instance, generic-heavy indices were mostly flat. Teva’s underperformance earlier in the year is turning into outperformance as of Q4 2025 after its big jump. If we compare Teva’s 3-year performance (~+142%) to, say, the NYSE Arca Pharma Index (DRG) or an ETF like XPH (pharma ETF), Teva likely beat them, given those indices didn’t double. This reflects that Teva is in a recovery phase whereas many big pharma are in a stable or declining phase post-COVID boost.
In summary, competitively Teva is holding its ground and carving a new path. It remains the dominant force in generics (with all the pros and cons that brings), and it is now a niche player in specialty drugs with ambitions to grow that side. Its diversified model (generics + specialty) can be a strength – providing steady cash flow from generics and upside from novel drugs – but also means it faces a wide array of competitors. The company’s current strategy is to focus on what it does best (complex generics, biosimilars) and what it can win at (CNS/neuro specialty drugs), while exiting or deemphasizing areas where it’s weaker (commodity APIs, certain markets). This strategic focus is crucial in a competitive sector. If successful, Teva could end up in a unique sector position as a top-tier generics firm with a respectable specialty portfolio – somewhat akin to a smaller version of Novartis (which had Sandoz generics plus a big pharma arm) before it spun Sandoz off. Investors will be comparing Teva’s execution against both pure-generic peers (where Teva looks stronger on growth) and pure-specialty peers (where Teva looks cheaper on valuation). So far, Teva is showing that it can compete effectively on both fronts, which bodes well for its ability to navigate the competitive landscape.
Regulatory, Legal, and Product Development News
Regulatory and legal developments have been a pivotal part of Teva’s story, and as of late 2025, most of the “big ticket” issues are settled or moving in a favorable direction.
In terms of legal resolution, the most consequential was the opioid litigation. Teva was one of the numerous companies sued by U.S. states and local governments over the opioid crisis. In July 2022, Teva announced a landmark $4.35 billion nationwide settlement to resolve roughly 3,000 lawsuits alleging Teva’s role in the opioid epidemic [123]. Under this deal, Teva agreed to pay out $3.7 B in cash over 13 years, plus provide $1.2 B worth of its opioid reversal drug (naloxone) to communities [124]. This settlement (finalized in 2023 after Allergan sorted its portion) removed a huge uncertainty that had been hanging over Teva’s stock (investors had feared a potentially bankrupting judgment if things went poorly). Now, while $4+ billion is not trivial, the extended payout schedule and inclusion of medicine mean the annual cash impact (about $300M/year) is manageable for Teva’s ~$1.7B annual free cash flow. With the opioid deal in place, Teva can draw a line under that litigation and focus on operations – indeed, New York’s Attorney General called Teva’s settlement “another major step” toward addressing the crisis [125], allowing all parties to move forward.
Another significant legal issue was the DOJ investigations into price-fixing and kickbacks in the generics industry. In August 2023, Teva reached a settlement with the U.S. Department of Justice, agreeing to pay $225 M as a criminal penalty for price-fixing charges (in lieu of facing trial) [126], and an additional $25 M to resolve a related civil case on alleged Medicare kickbacks [127]. Teva did not have to plead guilty (it entered into a deferred prosecution agreement), and this settlement also closed a dark chapter that had spanned years of investigation. The $250M total was again a hit, but far less damaging than the potential of criminal convictions or multi-billion fines. By settling, Teva avoided exclusion from Medicare programs or other operational restrictions. This DOJ settlement, combined with the opioid one, means Teva has now addressed the two largest legal risks it faced. The only ongoing notable litigations are smaller-scale (like patent suits or local pricing matters). The QVAR inhaler antitrust case settlement for $35M in Oct 2025, as mentioned, is one such example of tying up loose ends [128]. There’s also been some price-fixing civil litigation by states (e.g., a coalition of states suing various generic firms), but Teva has been settling some of those too – Ohio’s AG, for instance, secured a $49M settlement from Teva and another firm in 2023 for generic price-fixing claims [129]. These amounts are not material to Teva’s finances, and resolving them helps clear Teva’s reputation and avoid jury trials.
Regulatory developments have been largely positive or neutral for Teva lately. The Inflation Reduction Act (IRA) in the U.S., which empowers Medicare to negotiate prices on top drugs, is a new factor. Teva’s products haven’t been among the first 10 drugs selected (those were mostly diabetes and cardiovascular drugs by bigger pharma), but Austedo could be a candidate in a few years if its sales keep rising sharply (Medicare negotiation picks will expand to more drugs by 2026–2028). Teva’s comment that IRA outcomes haven’t shaken its confidence in Austedo suggests that either Austedo wasn’t selected or any forthcoming negotiation is not expected to severely impact its 2027 sales target [130]. This is something to watch: if Austedo is subject to price negotiation, its revenue beyond 2027 might plateau. But at least until 2027, Teva seems confident it can grow it above $2.5B annually [131].
Another regulatory piece is the FDA’s stance on biosimilars and complex generics – the FDA has been encouraging of biosimilars (to foster competition) which helps Teva. In 2025, the FDA approved Teva’s generic of Saxenda (liraglutide) for weight loss [132], which was notable as GLP-1 drugs are a hot area. The FDA also approved Ajovy’s new indication for pediatric migraine [133]. Looking forward, Teva has some regulatory milestones: it expects to file an NDA for olanzapine LAI (a long-acting injectable antipsychotic) by end of 2025 [134]. If accepted, that could be approved in 2026. It also is involved with partner Sanofi on a novel antibody (duvakitug, anti-TL1A for ulcerative colitis and Crohn’s) entering Phase 3 as of late 2025 [135]. That indicates by maybe 2027 we could see results. Additionally, Teva’s respiratory pipeline (it had some asthma/COPD inhalers in development) and digital health efforts (e.g., digital inhaler systems) are areas that could yield product news, although none headline-worthy at the moment.
On the product development front, Teva’s strategy is a mix of internal R&D and partnerships:
- In neuroscience, beyond Austedo and Ajovy, they are developing Emrusolmin (TEV-56286) for Multiple System Atrophy, which got FDA Fast Track designation [136]. MSA is a rare neurodegenerative disease, so this is a higher-risk, higher-reward project (no approved treatments currently).
- In immunology, the partnership with Sanofi on the TL1A inhibitor (duvakitug) for inflammatory bowel disease is notable – TL1A is a new target, and if successful, that could be a multi-billion dollar opportunity (though very competitive, as multiple companies are chasing this target). Sanofi started Phase 3 in Oct 2025 [137], so progress here would be a story around 2026–27.
- In respiratory and allergy, Teva has long been a leader (they have ProAir inhalers, etc.). They are working on a “DARI” – Dual-action Asthma Rescue Inhaler – which reached Phase 3 enrollment targets by end of 2025 [138]. A novel rescue inhaler could be significant given the large asthma market.
- In biosimilars, by 2025 Teva launched at least three major ones (biosimilar Humira, Stelara, Soliris under brand names Simlandi, Selarsdi, Epysqli respectively [139]). Upcoming biosimilars could include one to Eylea or Lucentis in ophthalmology (Teva had a deal for a Lucentis biosimilar), and possibly Keytruda or other biologics in the late-2020s. Regulatory support for biosimilars remains strong, so we can expect Teva to continue to get approvals here.
One cannot forget Copaxone, Teva’s once top-selling multiple sclerosis drug. While generic competition has slashed its sales (and it’s no longer a growth area), there was a regulatory development: the FDA approved additional generic Copaxone competitors in recent years, which further eroded Teva’s share. Teva has managed to retain some Copaxone sales (~$1B annual run-rate) by shifting patients to a 40mg 3-times weekly version and through brand loyalty, but by 2025 that tailwind is basically gone. The good news is that Teva’s dependence on Copaxone is now minimal, so future regulatory hits to that product won’t significantly dent revenues.
Compliance and quality: Teva, as a big manufacturer, also deals with FDA inspections of its plants. There were no major public FDA warning letters or manufacturing issues reported in 2025 for Teva’s facilities, which is good – a few years back some generic companies (like Mylan) had plant issues. Teva did have to navigate the nitrosamine impurities issue that hit the industry (valsartan recalls etc.), but nothing headline-grabbing recently.
In summary, the regulatory and legal environment for Teva at this juncture is favorable and much clearer than before:
- Major litigations (opioid, price fixing) are resolved with defined settlements [140] [141].
- Smaller litigations are being settled for manageable sums [142].
- Regulatory policy (IRA) so far hasn’t hurt Teva’s key products in the immediate term [143].
- The FDA is approving Teva’s new products (generics and brands) at a steady clip, enabling the company to execute its pipeline.
- Teva’s own strategic moves (divesting API, focusing on core) are aligning with regulatory approvals to streamline the business.
Going forward, investors should monitor:
- Execution of settlements (Teva must meet its payment obligations on opioids, etc., but those are planned and likely already provisioned in accounts).
- Outcome of any remaining state lawsuits (a few states like New York initially didn’t join the opioid deal; most have by now, but finalization in all jurisdictions will end headlines about it).
- FDA approvals for pipeline assets (olanzapine LAI NDA submission/approval, any surprise issues).
- Pricing regulations – the U.S. election cycle could bring drug pricing back in focus; Teva as a generic maker ironically benefits from focus on lowering drug costs (since generics are cost-savers), but as a brand-drug owner, it has some exposure too.
- Patent litigation – e.g., Teva has a stake in the outcome of any patent fights on Austedo (though no known challengers yet) or Ajovy’s formulation, etc. Also, Teva itself sometimes sues others (or gets sued) over generics, but those are part of normal course of business.
All considered, Teva heads into 2026 with far fewer legal clouds than in years past and a regulatory climate that is manageable. The focus can thus shift more to business performance and growth, which is exactly what management and investors want.
Sources: Key information and data points in this report were derived from credible financial news and filings, including Reuters (earnings and legal updates) [144] [145] [146], Investing.com (earnings details and CEO quotes) [147] [148], Teva’s official press releases [149] [150], MarketBeat/StockAnalysis (analyst ratings and price targets) [151] [152], and Motley Fool/Nasdaq coverage (institutional stake and strategy insight) [153] [154]. These sources corroborate the financial figures, stock metrics, and qualitative assessments presented.
References
1. www.reuters.com, 2. www.reuters.com, 3. stockanalysis.com, 4. www.reuters.com, 5. www.investing.com, 6. www.investing.com, 7. www.investing.com, 8. www.investing.com, 9. www.investing.com, 10. www.investing.com, 11. www.tevapharm.com, 12. www.stocktitan.net, 13. www.investing.com, 14. www.investing.com, 15. www.marketbeat.com, 16. finance.yahoo.com, 17. simplywall.st, 18. simplywall.st, 19. www.marketbeat.com, 20. stockanalysis.com, 21. www.marketbeat.com, 22. www.marketbeat.com, 23. www.marketbeat.com, 24. www.marketbeat.com, 25. www.nasdaq.com, 26. www.nasdaq.com, 27. www.nasdaq.com, 28. www.nasdaq.com, 29. www.reuters.com, 30. www.reuters.com, 31. www.tevapharm.com, 32. www.reuters.com, 33. www.reuters.com, 34. www.justice.gov, 35. www.biospace.com, 36. www.tevapharm.com, 37. www.tevapharm.com, 38. www.tevapharm.com, 39. www.tevapharm.com, 40. www.tevapharm.com, 41. www.investing.com, 42. www.investing.com, 43. www.reuters.com, 44. www.reuters.com, 45. www.investing.com, 46. www.tevapharm.com, 47. www.tevapharm.com, 48. www.investing.com, 49. www.investing.com, 50. www.tevapharm.com, 51. www.tevapharm.com, 52. www.investing.com, 53. www.investing.com, 54. www.stocktitan.net, 55. www.stocktitan.net, 56. www.investing.com, 57. s24.q4cdn.com, 58. www.tevapharm.com, 59. www.tevapharm.com, 60. ir.tevapharm.com, 61. www.marketbeat.com, 62. www.fitchratings.com, 63. www.stocktitan.net, 64. www.nasdaq.com, 65. www.marketbeat.com, 66. www.reuters.com, 67. finance.yahoo.com, 68. simplywall.st, 69. www.marketbeat.com, 70. simplywall.st, 71. www.reuters.com, 72. www.reuters.com, 73. www.investing.com, 74. www.tevapharm.com, 75. www.nasdaq.com, 76. www.nasdaq.com, 77. www.nasdaq.com, 78. en.globes.co.il, 79. www.reuters.com, 80. www.reuters.com, 81. www.reuters.com, 82. www.tevapharm.com, 83. www.tevapharm.com, 84. www.marketbeat.com, 85. www.marketbeat.com, 86. stockanalysis.com, 87. www.marketbeat.com, 88. www.marketbeat.com, 89. stockanalysis.com, 90. www.tevapharm.com, 91. www.tevapharm.com, 92. www.tevapharm.com, 93. www.stocktitan.net, 94. finance.yahoo.com, 95. simplywall.st, 96. simplywall.st, 97. finance.yahoo.com, 98. www.tevapharm.com, 99. www.tevapharm.com, 100. www.tevapharm.com, 101. www.fitchratings.com, 102. www.macrotrends.net, 103. www.marketbeat.com, 104. www.marketbeat.com, 105. www.marketbeat.com, 106. www.marketbeat.com, 107. www.marketbeat.com, 108. finance.yahoo.com, 109. www.reuters.com, 110. stockanalysis.com, 111. stockanalysis.com, 112. www.tevapharm.com, 113. stockanalysis.com, 114. stockanalysis.com, 115. stockanalysis.com, 116. www.tevapharm.com, 117. www.nasdaq.com, 118. www.tevapharm.com, 119. www.nasdaq.com, 120. www.tevapharm.com, 121. finance.yahoo.com, 122. www.nasdaq.com, 123. www.reuters.com, 124. www.reuters.com, 125. www.reuters.com, 126. www.justice.gov, 127. www.reuters.com, 128. www.reuters.com, 129. www.ohioattorneygeneral.gov, 130. www.tevapharm.com, 131. www.tevapharm.com, 132. www.tevapharm.com, 133. www.tevapharm.com, 134. www.tevapharm.com, 135. www.tevapharm.com, 136. www.tevapharm.com, 137. www.tevapharm.com, 138. www.tevapharm.com, 139. www.tevapharm.com, 140. www.reuters.com, 141. www.biospace.com, 142. www.reuters.com, 143. www.tevapharm.com, 144. www.reuters.com, 145. www.reuters.com, 146. www.reuters.com, 147. www.investing.com, 148. www.investing.com, 149. www.tevapharm.com, 150. www.tevapharm.com, 151. stockanalysis.com, 152. www.marketbeat.com, 153. www.nasdaq.com, 154. www.nasdaq.com
